FDA approves first human trial for Paradromics' brain-computer interface that could restore speech for paralyzed patients ...

Nyxoah today announced a significant reimbursement win through the U.S. Centers for Medicare & Medicaid Services (CMS).

Austin-based neurotechnology Paradromics announced that it has received FDA approvals to start its clinical trials.

Nyxoah ( (NYXH)) has issued an announcement. On November 13, 2025, Nyxoah announced its unaudited third-quarter results for 2025, highlighting significant developments in its clinical trials and ...

Warning: This graphic requires JavaScript. Please enable JavaScript for the best experience. Over decades, the government has spent billions on disability payments ...

The Sleep Apnea feature is designed to help users detect potential symptoms of the condition by monitoring sleep patterns along with blood oxygen levels (SpO₂) via the BioActive sensor, alerting the ...

Plaintiffs are going to court to challenge CVS Caremark’s decision to stop covering Zepbound, a weight-loss drug that is also used to treat sleep apnea. Plaintiff Martin Hamburger filed his lawsuit in ...

At World Sleep 2025, a discussion group examined the emerging role of GLP-1 receptor agonists in obstructive sleep apnea (OSA), particularly tirzepatide (Zepbound), which late last year became the ...

FDA approval describes when the Food and Drug Administration (FDA) deems a medical product safe and effective for its intended use based on scientific data and testing. Before people use a medical ...